Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Eribulin activates the cGAS-STING pathway via the cytoplasmic accumulation of mtDNA

Charles S. Fermaintt, Leila Takahashi-Ruiz, Huiyun Liang, Susan L. Mooberry and April L. Risinger
Molecular Pharmacology July 26, 2021, MOLPHARM-AR-2021-000297; DOI: https://doi.org/10.1124/molpharm.121.000297
Charles S. Fermaintt
1Pharmacology, University of Texas Health Science Center at San Antonio, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles S. Fermaintt
Leila Takahashi-Ruiz
1Pharmacology, University of Texas Health Science Center at San Antonio, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huiyun Liang
2Pharmacology, UT Health San Antonio, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan L. Mooberry
3Pharmacology, Univ. TX Health Sci Center at San Antonio, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susan L. Mooberry
April L. Risinger
1Pharmacology, University of Texas Health Science Center at San Antonio, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for April L. Risinger
  • For correspondence: risingera@uthscsa.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Microtubule targeting agents (MTAs), including both microtubule stabilizers and destabilizers, are highly effective chemotherapeutic drugs used in the treatment of solid tumors and hematological malignancies. In addition to the shared ability of all MTAs to block cell cycle progression, growing evidence shows that different agents of this class can also have mechanistically distinct effects on non-mitotic microtubule-dependent cellular processes, including cellular signaling and transport. Herein, we test the biological hypothesis that MTAs used in the treatment of triple-negative breast cancer (TNBC) can differentially affect innate immune signaling pathways independent of their antimitotic effects. Our data demonstrate that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel, induces cGAS-STING-dependent expression of interferon β in both myeloid and TNBC cells. Activation of the cGAS-STING pathway by eribulin was further found to be mediated by the accumulation of cytoplasmic mitochondrial DNA. Together, these findings provide mechanistic insight into how eribulin can induce innate immune signaling independent of its antimitotic or cytotoxic effects.

Significance StatementMicrotubule targeted agents are often used in the treatment of breast cancer and, most recently, have been used in combination with immune checkpoint inhibitors to improve their efficacy. While all clinically approved MTAs share an antimitotic mechanism of action, their distinct effects on interphase microtubules can promote differential downstream signaling consequences. We show that the microtubule destabilizer eribulin, but not the microtubule stabilizer paclitaxel, activates the cGAS-STING innate immune signaling pathway through the accumulation of mitochondrial DNA in the cytoplasm.

  • Anti-cancer agents
  • Anti-mitotics
  • breast cancer
  • cancer
  • cancer chemotherapy
  • Microtubules
  • © 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution CC BY License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Next
Back to top

In this issue

Molecular Pharmacology: 102 (3)
Molecular Pharmacology
Vol. 102, Issue 3
1 Sep 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Eribulin activates the cGAS-STING pathway via the cytoplasmic accumulation of mtDNA
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Eribulin activates cGAS-STING via mtDNA accumulation

Charles S. Fermaintt, Leila Takahashi-Ruiz, Huiyun Liang, Susan L. Mooberry and April L. Risinger
Molecular Pharmacology July 26, 2021, MOLPHARM-AR-2021-000297; DOI: https://doi.org/10.1124/molpharm.121.000297

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Eribulin activates cGAS-STING via mtDNA accumulation

Charles S. Fermaintt, Leila Takahashi-Ruiz, Huiyun Liang, Susan L. Mooberry and April L. Risinger
Molecular Pharmacology July 26, 2021, MOLPHARM-AR-2021-000297; DOI: https://doi.org/10.1124/molpharm.121.000297
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Regulation and Mechanisms of ImKTX58 on KV1.3 Channel
  • Human mAb 3F1 Targeting the Functional Epitopes of Siglec-15
  • Effects of Small Molecule Ligands on ACKR3 Receptors
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics